Rapid communication · 29 May 2025
Conference abstractPublished 2011
Molecular basis of drug action at the glucagon-like peptide 1 receptor
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The glucagon-like peptide-1 (GLP-1) receptor is a member of the family B G proteincoupled receptors (GPCRs) that contains many important drug targets. Its natural ligand, GLP-1, is a gluco-incretin hormone that plays an important physiological role in maintaining blood glucose homeostasis and holds promise as an very eff ective therapeutic drug for the treatment of type 2 diabetes. Understanding the molecular basis of ligand binding and activation of these receptors will facilitate the rational design of receptoractive drugs. However, the mechanisms underlying binding and activation of this family of receptors are poorly understood and the development of small-molecule ligands is problematic. Insights into the structure of the predominant ligand binding aminoterminal domain have substantially advanced with the solution of three-dimensional structures of the ligand-bound amino terminus of the GLP-1 receptor and several other family members. However, how family B ligands bind and activate their intact receptors is not yet clear. Receptor mutagenesis studies have suggested a two-domain tethering mechanism for activation of family B GPCRs in which the carboxyl-terminal region of the peptide binds to the amino-terminal domain of the receptor, while the amino-terminal region of the peptide interacts with the receptor core. Insights from our photoaffi nity labeling studies on the GLP-1 receptor are consistent with this mechanism, while also suggesting some variation in binding sites among family members. Th ese fi ndings should help the development and refi nement of novel receptor-active therapeutics targeting the GLP-1 receptor and all other members in this family.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Maoqing Dong”
- BylineArticles whose byline prints “Laurence J. Miller”